Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.? The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.
| Revenue (Most Recent Fiscal Year) | $13.63M |
| Net Income (Most Recent Fiscal Year) | $-186.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 11.34 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.52 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1318.93% |
| Net Margin (Trailing 12 Months) | -1318.93% |
| Return on Equity (Trailing 12 Months) | -47.17% |
| Return on Assets (Trailing 12 Months) | -34.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.81 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.52 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.32 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.49 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 114.60M |
| Free Float | 108.29M |
| Market Capitalization | $151.28M |
| Average Volume (Last 20 Days) | 1.72M |
| Beta (Past 60 Months) | 2.32 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.51% |
| Percentage Held By Institutions (Latest 13F Reports) | 97.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |